Mining the methylome for early indicators of human disease

Imagine a world in which a single blood draw can be used to detect and enable early treatment of many different diseases. That’s the future we’re creating at Adela.

about adela

Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease.

Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre.

Adela is initially planning to develop the technology for use across the entire cancer continuum—for detection, diagnosis and management of disease.

our values

Teamwork

We prioritize the success of the team over individual achievement.

Resilience

We have the capacity to adapt quickly, navigate uncertainty, and turn failures into opportunities.

Integrity

We are uncompromising in our adherence to strong ethical principles and values.

Flexible-Work

We give each other the trust and autonomy to take care of ourselves without compromising our commitments to each other.

Curiosity

We’re open minded and interested in understanding.

team

The members of Adela’s team are pioneers in the fields of cancer detection, epigenetics and liquid biopsy.

Allison Bogosian

Chief Human Resources Officer

Allison Bogosian

JD

Scott Bratman

Chief Executive Officer

Scott Bratman

MD, PhD

Daniel De Carvalho

Chief Scientific Officer

Daniel De Carvalho

PhD

Anne-Renee Hartman

Chief Medical Officer

Anne-Renee Hartman

MD

Priscilla Huang

Senior Vice President, Finance & Treasurer

Priscilla Huang

MBA

Karla Jarvis

Senior Vice President, General Counsel & Secretary

Karla Jarvis

JD, MPH

Chris Parker

Chief Business Officer

Chris Parker

Betsey Rapp

Vice President, Commercial

Betsey Rapp

MBA

Alan Williams

Chief Operating Officer

Alan Williams

PhD

To view additional members of Adela's talented team, visit us on LinkedIn.

board of directors

Lisa Alderson
MBA
Founder, Genome Medical
David Bonita
MD, MBA
General Partner, OrbiMed
Scott Bratman
MD, PhD
Co-founder & CEO, Adela
Paul Brown
PhD
Board Member for Decheng Capital
Andrew ElBardissi
MD
Partner, Deerfield Management
Maneesh Jain
PhD
Co-Founder, Adela
CEO, Mirvie
David Scheer
MBA
Co-founder & Board Chair, Adela
President, Scheer & Company
Robert Weisskoff
PhD, MBA
Partner, F-Prime

scientific advisory board

Gary Bader
Gary Bader
PhD

Professor, Department of Molecular Genetics at The Donnelly Centre at the University of Toronto

Sarah-Jane Dawson
Sarah-Jane Dawson
MBBS, FRACP, PhD

Professor of Medical Oncology at the University of Melbourne, Co-Head of the Cancer Biology & Therapeutics Program and Head of the Molecular Biomarkers & Translational Genomics Laboratory at the Peter MacCallum Cancer Centre

 Brian Druker
Brian Druker
MD

Director of the Knight Cancer Institute, Associate Dean for Oncology of the OHSU School of Medicine, and the JELD-WEN Chair of Leukemia Research

Allan Hackshaw
Allan Hackshaw
MSc, PhD

Professor of Epidemiology & Medical Statistics at University College London (UCL), and Director of the Cancer Research UK & UCL Cancer Trials Centre

Sylvia K. Plevritis
Sylvia K. Plevritis
MS, PhD

Professor and Chair of Biomedical Data Science, Professor of Radiology, and Program Director of the Biomedical Informatics Graduate Training Program at Stanford University

James Zou
James Zou
PhD

Assistant Professor of Biomedical Data Science at Stanford University and Chan-Zuckerberg Investigator

Investors